GlycoMimetics’ shares plunge as Phase III sickle cell disease trial fails
Pfizer, which had been running the trial of rivipansel in SCD, reported that it had failed on its primary and key secondary endpoints.
rivipansel
Pfizer, which had been running the trial of rivipansel in SCD, reported that it had failed on its primary and key secondary endpoints.